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Abstract
African American Men are 65% more likely to develop prostate cancer and are twice as likely to
die of prostate cancer, than are Caucasian American Males. The explanation for this glaring health
disparity is still unknown; although a number of different plausible factors have been offered
including genetic susceptibility and gene-environment interactions. We favor the hypothesis that
altered gene expression plays a major role in the disparity observed in prostate cancer incidence
and mortality between African American and Caucasian American Males. To discover genes or
gene expression pattern(s) unique to African American or to Caucasian American Males that
explain the observed prostate cancer health disparity in African American males, we conducted a
micro array pilot project study that used prostate tumors with a Gleason score of 6. We compared
gene expression profiling in tumors from African-American Males to prostate tumors in Caucasian
American Males. A comparison of case-matched ratios revealed at least 67 statistically significant
genes that met filtering criteria of at least +/- 4.0 fold change and p < 0.0001. Gene ontology terms
prevalent in African American prostate tumor/normal ratios relative to Caucasian American
prostate tumor/normal ratios included interleukins, progesterone signaling, Chromatin-mediated
maintenance and myeloid dendritic cell proliferation. Functional in vitro assays are underway to
determine roles that selected genes in these onotologies play in contributing to prostate cancer
development and health disparity.
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Introduction
African American males (AAM) have a 1.6 increased risk
of developing prostate cancer (PCa), and a 2.5 fold
increased mortality rate relative to Caucasian American
males (CAM) [1] The explanation for this greater PCa bur-
den in African Americans, still unclear, is probably multi-
factorial and may include diet, access to care, racial differ-
ences in PCa treatment, socioeconomic status, attitudes
about care and or differences in gene expression or gene-
environment [2-4]. The aim of this pilot project study is to
uncover gene expression differences that explain PCa
health disparity in AAM.
Methods
Acquisition of samples
This pilot project study was conducted using snap frozen
PCa tumors and non-tumor matched controls. Authoriza-
tion for tumor tissue used in this study was obtained
through IRB approved protocols from Florida A&M Uni-
versity and from the H. Lee Moffitt Cancer Center. Selec-
tion of prostate tissue from the Moffitt Cancer Center
Tissue Bank was made based on race/ethnicity, availabil-
ity of tumors with same Gleason grade/score. Due to the
limited tissue availability, this pilot project used a total of
16 prostate tissue samples. We used four snap frozen PCa
tumors and four matched controls from CAM men and
four snap frozen PCa tumors and four matched controls
from AAM. All PCa tumors in this study had a Gleason
score of 3+3 = 6. The 3+3 designation refers to the histo-
logical pattern or grade of the prostate cells. For example,
if 95% or more of the tumor is composed of one pattern,
the corresponding number is counted twice, thus an entire
moderately differentiated tumor would be scored as 3+3 =
6. A Gleason score of 2–4 is low grade, 5–7 is intermediate
grade and 8–10 is high grade.
Caucasian tumor vs. normal: Case-paired t-test analysis Figure 1
Caucasian tumor vs. normal: Case-paired t-test analysis. A comparison of micro array data of tumor versus normal for 
prostate sample from CAM was analyzed using R-bioconductor. Infectious Agents and Cancer 2009, 4(Suppl 1):S3 http://www.infectagentscancer.com/content/4/S1/S3
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RNA isolation, probe preparation, hybridization and scans
Total RNA from excised tissue specimens was isolated
using the TRIzol Reagent (Invitrogen, Carlsbad, CA) and
the manufacturer's protocol. We prepared, labeled RNA
Targets for hybridization using protocols initially
described by Van Gelder et al. [5] Probe arrays were
scanned once at 1.5-μm resolution using the Affymetrix
Gene Chip Scanner 3000 at the Moffitt Cancer Institute.
Micro array data
Gene expression profiles were measured for each of the
micro dissected prostate tissue samples using the Affyme-
trix U133A human arrays. Each of the 8 prostate tumors
and 8 matched control samples underwent single hybrid-
ization and was arrayed individually (i.e. samples were
not pooled). Data from the micro array CEL files was
uploaded to R-bioconductor for analysis. Gene changes
were then selected using the Significance Analysis of
Micro arrays (SAM) technique of Tusher et al. [6]. We
paired normal tissue samples with the tumor samples
from the same individuals for each race group. The results
of these case paired t-tests are described below.
African American male tumor vs. normal: case-paired t-test analysis Figure 2
African American male tumor vs. normal: case-paired t-test analysis. A comparison of micro array data from tumor 
versus normal for the prostate sample from African American (AA) Males was analyzed using R-bioconductor. This figure 
shows (1) a cluster gram of differentially expressed genes in the three prostate tumor sample vs. the three matching non-
tumor prostate tissue in African American males; (2) an MA plot is also shown in the lower left of this figure and (3) a Volcano 
Plot depicting additional information about these differentially expressed genes is shown in the lower right of this figure. The 
cluster gram shows a high degree of variation from among AA tumor samples and among AA normal samples. The Volcano and 
MA plots both showed an absence of high p-values and an absence of high fold change.Infectious Agents and Cancer 2009, 4(Suppl 1):S3 http://www.infectagentscancer.com/content/4/S1/S3
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Results
Results of the CAM case paired t-test
Approximately 100 genes clustered to give a distinct signal
indicating a subset of genes that were up regulated in CAM
prostate tumors (see lighter pattern in cluster gram, Figure
1) but down-regulated (see darker pattern in cluster gram,
Figure 1) in normal tissue of CAM. Genes listed in the
cluster gram in Figure 1 included protocadherin 8 (down
regulated 2.2 fold) and Cystatin SN (down regulated 2.3
fold). However, the filtering criteria of 4.0 fold change
and p < 0.0001 were not met for any of the 100 genes that
resulted from this paired t-test; hence these genes will not
be discussed. In the Volcano plot on lower right side of
Figure 1 the x-axis denotes fold change (a minus 2 value
represents a negative 2.0 fold change) and y axis denotes
minus the log of p-value; hence a y-axis value of 1.0, 2.0
and 3.0 represents a p-value of 0.01, 0.001 and 0.0001
respectively).
Results of the AAM case paired t-test
The raw data was reduced to a list of 100 genes, repre-
sented in the cluster gram in Figure 2. Pairing normal tis-
sue samples with the tumor samples for African American
Males, we observed a high degree of genetic variance
among tumor samples and non-tumor samples. Hence, it
was impossible to find differentially expressed genes that
met the filtering criteria of 4.0 fold change and p < 0.0001.
Overlap of case paired t-test for AAM & CAM gene lists
Figure 3 shows a comparison of the top 100 genes from
the AAM profile to the top 100 genes from CAM profiles
showed only one gene common between these differen-
tially expressed gene lists; that gene was a Transcription
Elongation Factor A (SII) like-7 gene proteins (TCEAL 7).
Case matched ratios-race group test
Figure 4 shows the result of comparing AAM case matched
ratios to CAM case matched ratios. We successfully con-
trolled for the AAM high degree of genetic variation and
were able to identify 67 differentially expressed genes in
AAM compared to CAM.
Case-matched ratios-test for race specific expression 
trends
Those genes found to be differentially expressed in AAM
were clustered using hierarchical cluster analysis to visual-
ize the pattern of gene expression for AAM tumor/normal
ratio to the CAM tumor/normal ratio. The key for sample
description is shown next to the heat map to the right of
the cluster gram, The first three horizontal rows of the
cluster gram are designated as CA ratio 1–3 and represent
three of the four CAM PCa tumor vs control data sets used
in this experiment. The AA ratio 1–4 represents the four
AAM PCa tumor vs control data sets used. These clustered
genes represented the top 100 genes from our ratios test
for race specific gene expression trends (highest p-value
observed was 9.28 E-06; lowest p-value observed 0.002).
The cluster gram in Figure 5 showed that genes up regu-
lated in AAM are simultaneously down regulated in CAM.
Gene ontology enrichment
Table 1 shows the significant gene ontology terms affected
in AAM tumor/normal case matched ratios relative to
CAM tumor/normal case matched ratios. Terms most
prevalent among differentially expressed genes in AAM
are interleukins, chromatin-mediated maintenance, pro-
gesterone signaling and myeloid dendritic cell differentia-
tion.
Discussion
The purpose of this pilot project study was to search for
genes unique to African American or Caucasian American
Males that explain the observed PCa health disparity
between the two races. The novel findings of this study 
Overlaps of case-paired t-test for African American male  (tumor vs. normal) and Caucasian American Males (tumor vs.  normal) gene lists Figure 3
Overlaps of case-paired t-test for African American 
male (tumor vs. normal) and Caucasian American 
Males (tumor vs. normal) gene lists. A comparison of 
the top 100 genes from the CA tumor vs. normal gene list to 
the top 100 genes from the AA tumor vs. normal top 100 
genes revealed that there was only one gene common to 
both these gene lists. That gene is TCEAL, a transcription 
elongation factor A-like 7 gene.Infectious Agents and Cancer 2009, 4(Suppl 1):S3 http://www.infectagentscancer.com/content/4/S1/S3
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Table 1: Gene Ontology Enrichment
GOBPID Pvalue OddsRat ExpCount Count Size Term
GO:0042091 0.00468 lnf 0.00468 1 1 interleukin-10 biosynthetic process
GO:0016340 0.00468 Inf 0.00468 1 1 calcium-dependent cell-matrix adhesion
GO:0045082 0.00468 lnf 0.00468 1 1 positive regulation of interleukin-10 biosynthetic process
GO:0045074 0.00468 Inf 0.00468 1 1 regulation of interleukin-10 biosynthetic process
GO:0007275 0.00536 2.23501 9.72558 18 2076 multicellular orgranismal development
GO:0048856 0.00558 2.2656 8.98071 17 1917 anatomical structure development
GO:0006478 0.00935 216.103 0.00937 1 2 peptidyl-tyrosine sulfation
GO:0035054 0.00935 216.103 0.00937 1 2 embryonic heart tube anteriorlposterior pattern formation
GO:0045366 0.00935 216.103 0.00937 1 2 regulation of interleukin-13 biosynthetic process
GO:0045368 0.00935 216.103 0.00937 1 2 positive regulation of interleukin-13 biosynthetic process
GO:0032613 0.00935 216.103 0.00937 1 2 interleukin-10 production
GO:0043283 0.01001 1.9026 20.8238 30 4445 bipolymer metabolic process
GO:0048731 0.01327 2.16651 7.43942 14 1588 system development
GO:0007399 0.01366 2.76046 3.19501 8 682 nervous system development
GO:0048617 0.01399 108.043 0.01405 1 3 embryonic foregut morphogenesis
GO:0042097 0.01399 108.043 0.01405 1 3 interleukin-4 biosynthetic process
GO:0046487 0.01399 108.043 0.01405 1 3 glyoxylate metabolic process
GO:0042231 0.01399 108.043 0.01405 1 3 interleukin-13 biosynthetic process
GO:0006538 0.01399 108.043 0.01405 1 3 glutamate catabolic process
GO:0045402 0.01399 108.043 0.01405 1 3 regulation of interleukin-4 biosynthetic process
GO:0045404 0.01399 108.043 0.01405 1 3 positive regulation of interleukin-4 biosynthetic process
GO:0048096 0.01399 108.043 0.01405 1 3 chromatin-mediated maintenance of transcription
GO:0032616 0.01399 108.043 0.01405 1 3 interleukin-13 production
GO:0050847 0.01399 108.043 0.01405 1 3 progesterone receptor signaling pathway
GO:0048339 0.01399 108.043 0.01405 1 3 paraxial mesoderm development
GO:0043011 0.01399 108.043 0.01405 1 3 myeloid dendritic cell differentiation
Case-matched ratios-race group tests Figure 4
Case-matched ratios-race group tests. Figure 4 depicts a Volcano plot on the left and a Modified MA plot on the right. 
The volcano plot shows the presence of genes (represented by dots) that have high gene expression profile changes and that 
are also highly statistically significant as evidenced by the p-values and the large fold change values (genes of interest fall above 
the dashed bold line). On the volcano plot, the x-axis denotes fold change of the Caucasian samples (i.e., a minus 2 represents 
a negative 2.0 fold change of tumor vs. normal) and the y axis denotes fold change of the African American samples. The mod-
ified MA plot shows fold change on the axis and intensity on the x-axis. The dots in the dashed squares in the upper left hand 
corner of the MA plot contains genes whose fold change values met our filtering criteria of positive in CA and negative in AA. 
The lower right dashed square contains genes that met our filtering criteria of positive in AA and negative in CA.    Infectious Agents and Cancer 2009, 4(Suppl 1):S3 http://www.infectagentscancer.com/content/4/S1/S3
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resulted in the identification of at least four candidate
genes that warrant further investigation as to their role in
PCa health disparity. First we observed that TCEAL 7
expression in PCa tumor and in non-tumor tissue was
higher in CAM compared to AAM. The TCEAL7 gene mod-
ulates transcription in a promoter context-dependent
manner. Moreover, a recent study [7] has implicated
TCEAL 7 as a cell death regulatory protein frequently inac-
tivated by methylation in ovarian cancer. These authors
showed that when re-expressed in cancer cell lines, TCEAL
7 induces cell death and reduces colony formation; thus
suggesting that TCEAL 7 functions as a tumor suppressor
protein. Because TCEAL 7 expression is slightly higher in
CAM than in AAM it is interesting to speculate that
increased expression of TCEAL 7 in CAM may correlate
with increased suppression of prostate tumors in CAM but
decreased prostate tumor suppression in AAM.
The second set of novel findings in this study was the
identification of gene ontology (GO) terms and pathways
that are prevalent in the 67 down-regulated genes (see
Table 1). The GO terms most prevalent in AAM were inter-
leukins, progesterone signaling and chromatin-mediated
maintenance. Genes associated with these GO ontologies,
which were decreased in expression in AAM compared to
CAM, were Histone Deacetylase 11 or HDAC 11 (down
regulated by 4.4876 fold); Interferon regulatory factor 4
(down regulated by 4.2142 fold), and the progesterone
receptor (down regulated by 2.7830 fold). HDAC is an
emerging oncology target. HDAC regulates gene expres-
Case-matched ratios-race group tests for specific expression trends Figure 5
Case-matched ratios-race group tests for specific expression trends. A cluster gram is shown in Figure 5. Those 
genes found to be differentially expressed were clustered using hierarchical cluster analysis to visualize the pattern of gene 
expression for each sample. Samples which represents the gene expression pattern that results when CA tumor/CA normal 
ratio is compared to AA tumor/AA Normal. The heat map indicates that blue represents highly expressed genes, while yellow 
represents under expressed genes; the black color on the heat map represented equal expression relative to control.Publish with BioMed Central    and   every 
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sion and overexpressed or sustained HDAC activity,
occurring in some cancer cells, results in deacetylation of
the histone tails or histone hypoacetylation. Histone
hypoacetylation results in more closed or tightly packaged
chromatin structure in which certain genes may become
inaccessible to transcription factors and hence will not get
transcribed. Such events are being studied aggressively as
a plausible mechanism for limiting or silencing tumor
suppressor genes. We have yet to discover the significance
of HDAC 11 down regulation in AAM samples compared
to CAM samples in this pilot project study. The finding
that the progesterone receptor is down regulated in AAM
relative to CAM samples is very intriguing in light of the
fact that decreased progesterone receptor expression con-
tributes to poor prognosis for breast cancer in African
American women. That this pilot project data underscores
the prevalence of interleukins is noteworthy because a
report [8] on tumor immunological differences between
African Americans and European American Males was
published as this data was being summarized. Taken
together, this study revealed 67 genes that are differen-
tially expressed in AAM prostate tumors, compared to
CAM. Functional assay studies are underway to investigate
the role at least four of these genes and the role that they
play in prostate cancer development and health disparity.
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